Amphastar Pharmaceuticals
AMPH
134 hedge funds and large institutions have $478M invested in Amphastar Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 50 reducing their positions, and 15 closing their positions.
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
3.57% more ownership
Funds ownership: 47.43% → 51% (+3.6%)
1% more capital invested
Capital invested by funds: $471M → $478M (+$6.53M)
1% more funds holding
Funds holding: 133 → 134 (+1)
6% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 50
96% less call options, than puts
Call options by funds: $19K | Put options by funds: $496K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$12.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$8.61M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$8.23M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$5.99M |
| 5 |
SAM
Silvercrest Asset Management
New York
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.65M |
| 2 |
ACM
Argent Capital Management
St Louis,
Missouri
|
-$3.97M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.43M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$1.61M |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
-$979K |
AMPH Hedge Fund Activity: Q3 2019 in Review
134 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2019, worth a combined $478M — up 1.4% from $471M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AMPH positions and 15 closed out — a net gain of 2 holders — while 47 added to existing stakes and 50 trimmed.
The largest buyer was VOYA Investment Management, adding an estimated $12.2M. The largest seller was Nuveen, cutting an estimated $5.65M.
- 134 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2019, up from 133 in Q2 2019.
- Funds reported $478M of Amphastar Pharmaceuticals stock for Q3 2019, up 1.4% quarter-over-quarter.
- 17 funds opened new Amphastar Pharmaceuticals positions in Q3 2019 and 15 closed out, a net change of +2 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2019 was VOYA Investment Management, an estimated $12.2M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2019 was Nuveen, an estimated $5.65M sold.
Based on aggregated 13F filings for Q3 2019.